Compare Deutsche Bank AG (DB) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Johnson & Johnson — how do they compare? Deutsche Bank AG trades at $33.68 (market cap $62.42B), while Johnson & Johnson trades at $259.01 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 9.9× Deutsche Bank AG's market cap, and Deutsche Bank AG pays the higher dividend (3.46%). Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Johnson & Johnson for 129 Days on average.
| DB | JNJ | |
|---|---|---|
Market Cap | $62.42B | $618.09B |
Volume | 2,918,760 | 6,050,983 |
Sector | Financials | Health |
52-Week High | $41.56 | $278.43 |
52-Week Low | $28.37 | $186.00 |
Typical Hold Time | 80 Days | 129 Days |
Enterprise Value | $77.06B | $646.37B |
Dividend Yield | 3.46% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% on concerns about Q3 investment banking revenue. The stock shows attractive valuation metrics with P/E of 9.09 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B and profit margin expanding to 21.59%. Technical indicators signal bearish momentum with the price near key support at $33. Recent news highlights the bank's strategic focus on wealth management growth and 2028 return targets.
The outlook remains balanced - strong fundamentals and undervaluation provide upside potential, but near-term headwinds in investment banking and technical weakness suggest cautious optimism. Key risks include execution on strategic targets and market-sensitive revenue streams, while analyst consensus leans neutral with 58% hold ratings.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
